Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2017

Open Access 01-12-2017 | Case report

Malignant acrospiroma: a case report in the era of next generation sequencing

Authors: Maria Diab, Ali Gabali, Muaiad Kittaneh

Published in: BMC Cancer | Issue 1/2017

Login to get access

Abstract

Background

Malignant acrospiroma is a rare tumor of the eccrine sweat glands accounting for around 6% of all malignant eccrine tumors. Typically, it presents as large ulcerated nodules, and diagnosis can be challenging as it has great overlap with its benign counterpart.

Case presentation

We herein report a case of acral malignant acrospiroma, initially treated with surgical excision and adjuvant radiotherapy. After metastatic disease was confirmed, subject received multiple lines of chemo- as well as targeted therapy. Genomic testing was also done using next generation sequencing.

Conclusion

To the best of our knowledge, this is the first case of acral malignant acrospiroma with reported next generation sequencing results.
Literature
1.
Mehregan AH, Hashimoto K, Rahbari H. Eccrine adenocarcinoma. A clinicopathologic study of 35 cases. Arch Dermatol. 1983;119(2):104–14.CrossRefPubMed
2.
Tingaud C, et al. Lymph node location of a clear cell hidradenoma: report of a patient and review of literature. J Cutan Pathol. 2016;43(8):702–6.CrossRefPubMed
3.
Crowson AN, Magro CM, Mihm MC. Malignant adnexal neoplasms. Mod Pathol. 2006;19(Suppl 2):S93–S126.CrossRefPubMed
4.
Long WP, Dupin C, Levine EA. Recurrent malignant acrospiroma. Treatment by chest wall excision. Dermatol Surg. 1998;24(8):908–12. discussion 911-2CrossRefPubMed
5.
Gortler I, et al. Metastatic malignant acrospiroma of the hand. Eur J Surg Oncol. 2001;27(4):431–5.CrossRefPubMed
6.
Kauderer C, Clarke HD, Fatone CT. Malignant eccrine acrospiroma. A case study. J Am Podiatr Med Assoc. 1995;85(2):116–7.CrossRefPubMed
7.
Cruz DJ. Sweat gland carcinomas: a comprehensive review. Semin Diagn Pathol. 1987;4(1):38–74.PubMed
8.
Deckelbaum S, et al. Eccrine poromatosis: case report and review of the literature. Int J Dermatol. 2014;53(5):543–8.CrossRefPubMed
9.
Ogilvie JW. Malignant eccrine acrospiroma. A case report. J Bone Joint Surg Am. 1982;64(5):780–2.CrossRefPubMed
10.
Cyrlak D, Barr RJ, Wile AG. Malignant eccrine acrospiroma of the breast. Int J Dermatol. 1995;34(4):271–3.CrossRefPubMed
11.
Wilson KM, Jubert AV, Joseph JI. Sweat gland carcinoma of the hand (malignant acrospiroma). J Hand Surg [Am]. 1989;14(3):531–5.CrossRef
12.
Andreoli MT, Itani KM. Malignant eccrine spiradenoma: a meta-analysis of reported cases. Am J Surg. 2011;201(5):695–9.CrossRefPubMed
13.
Bandyopadhyay A, et al. Malignant acrospiroma of chest and abdominal wall treated with chemotherapy. Indian J Dermatol. 2013;58(3):241.CrossRef
14.
Wenzel E, et al. Malignant eccrine acrospiroma: a case report. J Am Podiatr Med Assoc. 2012;102(3):247–51.CrossRefPubMed
15.
Piris A, et al. Epidermal growth factor receptor gene status by fluorescence in situ hybridization in malignant, atypical, and benign hidradenomas. Am J Dermatopathol. 2010;32(6):586–92.CrossRefPubMed
16.
Wildemore JK, Lee JB, Humphreys TR. Mohs surgery for malignant eccrine neoplasms. Dermatol Surg. 2004;30(12 Pt 2):1574–9.PubMed
17.
Keasbey LE, Hadley GG. Clearcell hidradenoma; report of three cases with widespread metastases. Cancer. 1954;7(5):934–52.CrossRefPubMed
18.
19.
20.
Lopez-Burbano LF, et al. Malignant clear-cell hidradenoma. Plast Reconstr Surg. 1987;80(2):300–3.CrossRefPubMed
21.
Lerner A, et al. Complete response of metastatic malignant hidradenocarcinoma to capecitabine treatment. Arch Dermatol. 2011;147(8):998–9.CrossRefPubMed
22.
Battistella M, et al. Sunitinib efficacy in the treatment of metastatic skin adnexal carcinomas: report of two patients with hidradenocarcinoma and trichoblastic carcinoma. J Eur Acad Dermatol Venereol. 2010;24(2):199–203.CrossRefPubMed
23.
Harari PM, et al. The role of radiotherapy in the treatment of malignant sweat gland neoplasms. Cancer. 1990;65(8):1737–40.CrossRefPubMed
24.
Behboudi A, et al. Clear cell hidradenoma of the skin-a third tumor type with a t(11;19)--associated TORC1-MAML2 gene fusion. Genes Chromosom Cancer. 2005;43(2):202–5.CrossRefPubMed
25.
Kazakov DV, et al. Cutaneous hidradenocarcinoma: a clinicopathological, immunohistochemical, and molecular biologic study of 14 cases, including Her2/neu gene expression/amplification, TP53 gene mutation analysis, and t(11;19) translocation. Am J Dermatopathol. 2009;31(3):236–47.CrossRefPubMed
26.
Bell D, et al. Next-generation sequencing reveals rare genomic alterations in aggressive digital papillary adenocarcinoma. Ann Diagn Pathol. 2015;19(6):381–4.CrossRefPubMed
Metadata
Title
Malignant acrospiroma: a case report in the era of next generation sequencing
Authors
Maria Diab
Ali Gabali
Muaiad Kittaneh
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2017
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-017-3217-5

Other articles of this Issue 1/2017

BMC Cancer 1/2017 Go to the issue

Research article

Expression of enhancer of zeste homolog 2 correlates with survival outcome in patients with metastatic breast cancer: exploratory study using primary and paired metastatic lesions

Research article

Elevation of tumour markers TGF-β, M2-PK, OV-6 and AFP in hepatocellular carcinoma (HCC)-induced rats and their suppression by microalgae Chlorella vulgaris

Research article

CpG promoter methylation of the ALKBH3 alkylation repair gene in breast cancer

Research article

Men’s perceptions of prostate cancer diagnosis and care: insights from qualitative interviews in Victoria, Australia

Research article

Acupuncture combined with methylcobalamin for the treatment of chemotherapy-induced peripheral neuropathy in patients with multiple myeloma

Research article

Urokinase-type plasminogen activator receptor (uPAR), tissue factor (TF) and epidermal growth factor receptor (EGFR): tumor expression patterns and prognostic value in oral cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits